Status:
COMPLETED
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Brigham and Women's Hospital
Massachusetts General Hospital
Conditions:
Hodgkin's Disease
Breast Cancer
Eligibility:
FEMALE
18-35 years
Phase:
NA
Brief Summary
The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.
Detailed Description
* Patients will receive tamoxifen orally once daily to be taken at home for 1 year. They will be asked to complete a daily drug log to keep track of the pills taken or missed. * Patients will also be ...
Eligibility Criteria
Inclusion
- Females diagnosed with Hodgkin's Disease at age \< 35 years
- \> 5 years from mantle or chest radiation
- Current age \> 30 years
- Has completed childbearing
- Willingness to discontinue use of oral contraceptives or other hormonal contraception for duration of the study
Exclusion
- History of secondary malignancy after Hodgkin's disease, except thyroid cancer of basal cell cancer
- Recurrence of Hodgkin's disease in the 5 years before study entry
- Current participation in any other cancer prevention study
- Current or prior use of tamoxifen
- Current use of coumadin
- History of deep venous thrombosis, pulmonary embolism, or a condition known to be associated with hypercoagulability
- History of cerebrovascular accident
- History of macular degeneration
- Current use of chemotherapy for benign disease
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00165308
Start Date
April 1 2001
End Date
June 1 2009
Last Update
July 9 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115